Previous 10 | Next 10 |
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...
NEW HAVEN, Conn., June 20, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the BMO Prescrip...
The following slide deck was published by Arvinas, Inc. in conjunction with this Read more ...
NEW HAVEN, Conn., June 06, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Goldman...
Bayer ( OTCPK:BAYRY ) will launch a joint venture with Arvinas (NASDAQ: ARVN ) aimed at developing protein degraders for crop protection. The partnership, which also includes a target-based pharmaceutical research collaboration, will leverage Arvinas' PROTAC technology with Bayer...
- $110M+ life sciences deal to develop novel PROTAC® candidates for patients with cardiovascular, oncological, and gynecological diseases, and to expand application of PROTAC® degraders to plant health - Bayer and Arvinas to launch a joint venture to develop targeted protein...
BERLIN , MONHEIM, Germany and WHIPPANY, N.J. , June 4, 2019 /PRNewswire/ -- Bayer today announced a collaboration with Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company based in New Haven, Connecticut . The new life science research partnership uniquely leverages the full...
The FDA has granted Fast Track designation to Arvinas' (NASDAQ: ARVN ), lead PROTAC protein degrader, ARV-110, for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed after treatment with two or more systemic therapies. More news...
NEW HAVEN, Conn., May 29, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrades disease-causing proteins, today announced that its lead PROTAC® protein degrader, ARV-110, has been granted Fast Track designatio...
Arvinas (NASDAQ: ARVN ): Q1 GAAP EPS of -$0.46 in-line. More news on: Arvinas, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial Officer Company is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential...
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann...